Urothelial Cancer

Guru P. Sonpavde, MD, discusses topline data from an exploratory analysis of CheckMate 901 in metastatic urothelial cancer.

Jacqueline Brown, MD, explains the need to determine optimal second-line bladder cancer treatments for use after enfortumab vedotin/pembrolizumab.

Jacqueline Brown, MD, discusses the current role of enfortumab vedotin plus pembrolizumab in bladder cancer and tips for early AE management.

The SunRISe-2 trial of TAR-200 plus cetrelimab in muscle-invasive bladder cancer not undergoing radical cystectomy is being discontinued.

Guru P. Sonpavde, MD, discusses initial data from a phase 1/2 trial of sacituzumab govitecan plus ipilimumab and nivolumab in metastatic urothelial cancer.

Andrea Necchi, MD, discusses treatment with TAR-200 by PD-L1 expression in BCG-unresponsive, high-risk non–muscle-invasive bladder cancer with CIS.

John K. Lee, MD, PhD, discusses safety considerations for enfortumab vedotin in the treatment of metastatic urothelial cancer.

Andrea Necchi, MD, discusses an analysis of the SunRise-4 trial evaluating TAR-200 plus cetrelimab in patients with muscle-invasive bladder cancer.

Adjuvant pembrolizumab generated a DFS benefit vs observation in patients with high-risk muscle-invasive bladder cancer after radical surgery.

BL-B01D1 displayed safety and preliminary efficacy in previously treated locally advanced or metastatic urothelial carcinoma.

Enfortumab vedotin plus pembrolizumab has been approved in Japan for first-line radically unresectable urothelial carcinoma.

Guru Sonpavde, MD, expands on findings from 2 key bladder cancer trials presented at the 2024 ESMO Congress.

Dingwei Ye, MD, PhD, discusses the initial efficacy and safety of BL-B01D1 in locally advanced or metastatic urothelial carcinoma.

Dingwei Ye, MD, PhD, discusses the safety and efficacy outcomes of a clinical trial evaluating BL-B01D1 in locally advanced or metastatic urothelial carcinoma.

Neoadjuvant TAR-200 plus cetrelimab elicited responses and was safe in muscle-invasive bladder cancer.

NIAGARA was the first phase 3 study to evaluate perioperative immunotherapy plus neoadjuvant chemotherapy in cisplatin-eligible muscle-invasive bladder cancer.

Joshua Linscott, MD, PhD, discusses the use of urinary cell-free tumor DNA for MRD detection prior to repeat resection in high-risk NMIBC.

The European Commission granted marketing authorization to frontline enfortumab vedotin plus pembrolizumab for unresectable/metastatic urothelial cancer.

Erdafitinib was approved by the European Commission for pretreated unresectable or metastatic urothelial carcinoma harboring FGFR3 alterations.

Enfortumab vedotin plus pembrolizumab has been approved by Health Canada for use in unresectable locally advanced or metastatic urothelial cancer.

Karl Semaan, MD, MSc, discusses the clinical advantages of liquid biopsy over tissue biopsies in detecting sarcomatoid renal cell carcinoma.

China’s National Medical Products Administration has approved enfortumab vedotin for adult patients with locally advanced or metastatic urothelial cancer.

Bradley McGregor, MD, discusses the clinical implications of the DAD-IO trial in patients with metastatic urothelial carcinoma.

Neil J. Shah, MBBS, discusses treatment patterns and clinical outcomes in metastatic renal cell carcinoma after an immuno-oncology/TKI combination.

A new drug application has been submitted to the FDA for UGN-102 inlow-grade, intermediate-risk non–muscle-invasive bladder cancer.